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C ardiovascular drugs and devices may havedifferent safety and efﬁcacy proﬁles incertain populations. Performance of sepa-
rate trials or subgroup analysis is important if there
is a biological reason, either intrinsic and/or extrinsic,
for a varied response to a therapy. For example,
compared with men, women have different body
size, hormonal milieu, sex-speciﬁc physiology, and
sociocultural inﬂuences. Randomized controlled tri-
als are generally powered for the primary outcome
in all enrolled individuals, and the results are gener-
alized to subgroups. Pre-speciﬁed or post-hoc
analyses of subgroups within a study are often
exploratory due to lack of randomization and small
numbers. Caution must be exercised in the number
of subsets examined due to the potential for chance
ﬁndings. In addition, interaction terms in statistical
models should only be pursued if there is an a priori
hypothesis being examined. In trials of percutaneous
coronary intervention (PCI), the low enrollment of
women has led to less robust data and the inability
to study the interaction between sex and other impor-
tant clinical characteristics, for example, diabetes
mellitus and chronic kidney disease (CKD), which
are associated with high rates of major adverse car-
diovascular events in PCI trials. In an effort to
examine the performance of drug-eluting stents
(DES) in women, the Society for Cardiovascular Angi-
ography and Interventions’ Women in Innovation
Initiative held a Gender Data Forum. Through collab-
orative efforts of cardiology societies, study investi-
gators, and industry, an individual patient-level*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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harnessing the power of numbers, the relationship
between renal function, DES platform, and adverse
outcomes in women is reported (1). The analysis in-
cluded 4,217 women receiving DES in a randomized
trial comparing DES and bare-metal stents (BMS), or 2
or more DES types, between 2002 and 2013. Earlier
trials were predominantly with ﬁrst-generation dura-
ble polymer sirolimus- and paclitaxel-eluting stents,
with 3 to 6 months duration of dual antiplatelet ther-
apy (DAPT), in patients with stable coronary artery
disease. Newer DES trials included durable polymer
everolimus- and zotarolimus-eluting stents and
biodegradable polymer stents. Higher-risk patients
including those with acute coronary syndrome were
included, and DAPT duration in general was longer at
6 to 12 months. Endpoints were adjudicated per pro-
tocol in each clinical trial, and the Academic Research
Consortium deﬁnition was used for stent thrombosis.
RENAL FUNCTION AND PCI OUTCOMES
IN WOMEN
The dataset included patients with moderate CKD;
however, patients with severe and end-stage renal
disease were excluded from the clinical trials. Out-
comes were compared in women with creatinine
clearance (CrCl) >60 ml/min, between 60 and 45
ml/min, and <45 ml/min. Among the women, only
14% had a CrCl of <45 ml/min. Two important trends
in women undergoing PCI with DES were observed.
First, as CKD worsened, major adverse cardiac events
increased. Speciﬁcally, moderate renal dysfunction
(CrCl <45 ml/min) was independently associated with
higher risks of death and myocardial infarction and a
trend toward stent thrombosis at 3 years. Second,
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40target lesion revascularization was low, around 6% at
3 years, and was not related to severity of CKD. The
efﬁcacy of DES in women, therefore, is not affected by
CKD, and outcomes are overwhelmingly driven by
nonculprit-related events with a small contribution
from stent thrombosis. The higher risk of stent
thrombosis in CKD is not only observed in women. In
a large, observational study of patients undergoing
elective DES, CKD was an independent predictor of
1-year deﬁnite or probable stent thrombosis (2).
STENT PLATFORM AND PCI OUTCOMES
IN WOMEN
The second focus of the analysis was a comparison
between ﬁrst- and newer-generation DES. In women,
independent of renal function, use of newer-
generation DES was associated with a lower risk of
both safety (cardiac death, myocardial infarction, and
stent thrombosis) and efﬁcacy (target lesion revascu-
larization) endpoints. This is in keeping with the
results of large randomized controlled trials and meta-
network analyses of DES types. The effect of this data
is small, because the ﬁrst-generation DES are no longer
in use (sirolimus-eluting stents) or are known to be
inferior to current DES (paclitaxel-eluting stents), and
the study could not evaluate individual stent types.
There may, for example, be different healing charac-
teristics of the newer-generation stents in women,
particularly in CKD patients. Currently, there is no data
to suggest a difference between newer-generation
durable polymer DES in women (3). Whether bio-
absorbable polymer DES offers an advantage inwomen
or CKD patients is unknown. In a virtual histology
intravascular ultrasound study comparing DES neo-
intimal characteristics in patients with and without
CKD, neoatherosclerosis was related to neointimal
volume, which was greater in patients with CKD (4).
Although differences in neointimal volume may not
translate into higher rates of clinical restenosis,
neoatherosclerosis is 1 potential mechanism of late
ischemic events in stents, including very late stent
thrombosis. Assessment of surrogates of healing with
intracoronary imaging may be an avenue to form
hypothesis-generating questions about novel DES
types.
IMPROVING OUTCOMES IN
INDIVIDUAL SUBGROUPS
Standard-dose clopidogrel remains the most common
P2Y12 inhibitor in PCI for stable coronary artery disease
and was used in the trials included in the current
analysis. Female sex and CKD, however, are bothassociated with high on-treatment platelet reactivity
(5,6). The association between residual platelet reac-
tivity and adverse outcomes is irrespective of sex
or renal function. Woman and patients with CKD,
therefore, may beneﬁt from a more aggressive or
tailored approach to DAPT. In a randomized controlled
trial of 370 patients with CKD and clopidogrel resis-
tance, double-dose compared with standard-dose clo-
pidogrel resulted in greater inhibition of platelet
aggregation and improved 1-month outcomes in
PCI patients, including stent thrombosis and major
adverse cardiac events, without increasing bleeding
(7). Generalizing data from large randomized con-
trolled trials, more potent P2Y12 antiplatelet agents
should be used inwomen andCKDpatients undergoing
PCI in the setting of acute coronary syndromes
unless contraindicated. The optimal duration of
DAPT in PCI subgroups has not been fully examined.
Prolonged DAPT reduces both stent thrombosis
and nonculprit myocardial infarction events but may
not translate into a mortality beneﬁt due to risk of
bleeding. In an Embase and Cochrane database
review, the beneﬁt of antiplatelet therapy in CKD pa-
tients was deemed uncertain (8).
Not addressed in the current study is the compari-
son of DES to BMS in CKD patients including those
with end-stage renal disease on dialysis. Although
there have been conﬂicting reports on whether the
efﬁcacy of DES is lower in CKD, it is clear that DES
are the preferred stent platform. In the RENAL-DES
(Randomized Comparison of Xience V and Multi-
Link Vision Coronary Stents in the Same Multi-vessel
Patient with Chronic Kidney Disease) trial, clinically
driven target vessel revascularization at 1 year was
markedly lower in DES: 2.7% versus 11.4% (p < 0.001)
(9). In a meta-analysis of DES compared with BMS
in end-stage renal disease, target lesion revasculari-
zation, target vessel revascularization, and major
adverse cardiovascular events were signiﬁcantly
lower with DES (10). In the listed trials, outcomes
according to sex were not reported. The atheroscle-
rotic milieu in CKD patients, with more diffuse and
complex disease, inﬂammation, and endothelial
dysfunction, may not attenuate the beneﬁt of DES,
but the disease in advanced stages may be more
optimally treated with surgical revascularization,
similar to patients with diabetes mellitus. In a recent
propensity-matched analysis of unselected patients
from Ontario, Canada, PCI with DES was compared
with coronary artery bypass grafting in patients
with CKD (CrCl <60 ml/min). During 3 years of follow-
up, coronary artery bypass graft patients had greater
survival and freedom from major adverse cardiac
and cerebrovascular events. Female sex was a
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41negative predictor of late mortality but had no effect
on the composite of late major adverse cardiac and
cerebrovascular events (11). In an analysis of the So-
ciety of Thoracic Surgeons National Adult Cardiac
Database, women undergoing coronary bypass more
often had CKD, and CKD was associated with higher
operative mortality and post-operative complications.
Female sex, however, was not independently associ-
ated with adverse outcomes (12).
CONCLUSIONS
Despite the enormity of data on current DES plat-
forms, there remains a need to examine subgroupsand interactions between subgroups to understand
the best device for the individual patient. Differences
in physiology and pharmacodynamics in women and
men necessitate equal representation in clinical
trials. Certain high-risk clinical subgroups, such as
patients with CKD or diabetes mellitus, also deserve
increased attention as both qualitative and quantita-
tive differences may be observed compared with
patients without these comorbidities.
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